Q-omics provides the consensus-scored OR4F13P profile across patient tissues and cancer cell-line models. OR4F13P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, OR4F13P is differentially expressed in 4, with the highest sampling consensus in KIRP. Additionally, OR4F13P RNA expression shows 9,804 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, KIRP, and UVM as cancer lineages where OR4F13P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR4F13P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR4F13P survival associations across molecular data types. OR4F13P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR4F13P RNA expression–survival associations across cancer types. High OR4F13P expression shows unfavorable associations in UCS, UVM, MESO, LUAD, ACC and THYM. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for OR4F13P RNA expression.
This table summarizes OR4F13P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for OR4F13P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR4F13P shows lower tumor expression in KICH and higher tumor expression in KIRP, HNSC and KIRC. The KIRP box plot shows higher OR4F13P RNA expression in tumor versus normal tissue (log2 FC = +0.060, t-test p = .005).
This table shows molecular features associated with OR4F13P in patient tissues and cancer cell lines. In patient samples, OR4F13P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
